Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy

被引：0
|
作者：
Basile, D. [1 ,2 ,3 ]
Broudin, C. [4 ,5 ]
Emile, J-F. [6 ,7 ]
Falcoz, A. [8 ]
Toullec, C. [9 ]
Bennouna, J. [10 ]
Louvet, C. [11 ]
Desrame, J. [12 ]
Fratte, S. [13 ,14 ]
Andre, T. [15 ]
Taieb, J. [16 ]
Svrcek, M. [17 ]
机构：
[1] Univ Udine, Dept Med DAME, Dept Hepatogastroenterol & Gastrointestina, Paris, France
[2] ULSS8 Ber, Dept Med Oncol, Vicenza, Italy
[3] Univ Paris Paris Descartes, Hop Europeen Georges Pompidou, AP HP, CARPEM,SIRIC, Paris, France
[4] Assistance Publ Hop Paris AP HP Ctr, Serv Anatomopathol Hop Europeen Georges Pompi, Paris, France
[5] Univ Paris, Fac Med, Paris, France
[6] Versailles Saint Quentinen Yvelines Univ, EA4340 Biomarqueurs & Essais Clin Cancerol & Onco, Dept Pathol, Boulogne, France
[7] Hop Ambroise Pare, AP HP, Boulogne, France
[8] Univ Bourgogne Franche Comte, INSERM, Etab Francais Sang Bourgogne Franche, UMR 1098,Methodol & Quality Life Unit Oncol, Besancon, France
[9] Inst St Catherine, Dept Digest Oncol, Avignon, France
[10] CHU Nantes, Digest & Lung Oncol Dept, Nantes, France
[11] Inst Mutualiste Montsouris, Oncol, Paris, France
[12] Hop Prive Jean Mermoz, Oncol, Lyon, France
[13] Hosp Belfort Montbeliard, Montbeliard, France
[14] Hosp Besancon, Besancon, France
[15] Hop St Antoine, Med Oncol, Paris, France
[16] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
[17] Sorbonne Univ, Hop St Antoine, Pathol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.910
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388MO
引用
收藏
页码：S533 / S533
页数：1
相关论文
共 50 条
  • [31] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kaadan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Ray, Asghari
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 132 - 133
  • [32] ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Baek, Moo-Jun
    [J]. ANNALS OF COLOPROCTOLOGY, 2015, 31 (03) : 81 - 81
  • [33] Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
    Zhan, Yixiang
    Ni, Kemin
    Liu, Zhaoce
    Xin, Ran
    Han, Qiurong
    Ping, Hangyu
    Liu, Yaohong
    Zhao, Xuanzhu
    Wang, Wanting
    Yan, Suying
    Sun, Jing
    Zhang, Qinghuai
    Wang, Guihua
    Zhang, Zili
    Zhang, Xipeng
    Hu, Xia
    Li, Guoxun
    Zhang, Chunze
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [34] Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
    Yixiang Zhan
    Kemin Ni
    Zhaoce Liu
    Ran xin
    Qiurong Han
    Hangyu Ping
    Yaohong Liu
    Xuanzhu Zhao
    Wanting Wang
    Suying Yan
    Jing Sun
    Qinghuai Zhang
    Guihua Wang
    Zili Zhang
    Xipeng Zhang
    Xia Hu
    Guoxun Li
    Chunze Zhang
    [J]. Scientific Reports, 13
  • [35] Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer.
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Gill, Sharlene
    Lim, Howard John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [36] Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
    Kyong Shin, Jung
    Ah Park, Yoon
    Wook Huh, Jung
    Hyeon Yun, Seong
    Cheol Kim, Hee
    Yong Lee, Woo
    Hyung Kim, Seok
    Yun Ha, Sang
    Cho, Yong Beom
    [J]. DISEASES OF THE COLON & RECTUM, 2023, 66 (08) : E801 - E808
  • [37] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
    P Li
    Y J Fang
    F Li
    Q J Ou
    G Chen
    G Ma
    [J]. British Journal of Cancer, 2013, 108 : 1238 - 1244
  • [38] Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
    Custodio, A.
    Moreno-Rubio, J.
    Aparicio, J.
    Gallego-Plazas, J.
    Yaya, R.
    Maurel, J.
    Higuera, O.
    Burgos, E.
    Ramos, D.
    Calatrava, A.
    Andrada, E.
    Lopez, R.
    Moreno, V.
    Madero, R.
    Cejas, P.
    Feliu, J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (02) : 398 - 403
  • [39] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
    Li, P.
    Fang, Y. J.
    Li, F.
    Ou, Q. J.
    Chen, G.
    Ma, G.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (06) : 1238 - 1244
  • [40] Features of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer
    Argyriou, A.
    Polychronopoulos, P.
    Iconomou, G.
    Koutras, A.
    Gourzis, P.
    Assimakopoulos, K.
    Kalofonos, H.
    Chroni, E.
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 : 111 - 111
12345